SFPQ rescues F508del-CFTR expression and function in cystic fibrosis bronchial epithelial cells

被引:0
|
作者
Parameet Kumar
Dharmendra Kumar Soni
Chaitali Sen
Mads B. Larsen
Krystyna Mazan-Mamczarz
Yulan Piao
Supriyo De
Myriam Gorospe
Raymond A. Frizzell
Roopa Biswas
机构
[1] School of Medicine,Department of Anatomy, Physiology and Genetics
[2] Uniformed Services University of the Health Sciences,Department of Cell Biology
[3] University of Pittsburgh,Laboratory of Genetics and Genomics
[4] School of Medicine,Department of Anatomy, Physiology and Genetics
[5] National Institute on Aging,undefined
[6] National Institutes of Health,undefined
[7] School of Medicine,undefined
[8] Uniformed Services University of the Health Sciences,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Cystic fibrosis (CF) occurs as a result of mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which lead to misfolding, trafficking defects, and impaired function of the CFTR protein. Splicing factor proline/glutamine-rich (SFPQ) is a multifunctional nuclear RNA-binding protein (RBP) implicated in the regulation of gene expression pathways and intracellular trafficking. Here, we investigated the role of SFPQ in the regulation of the expression and function of F508del-CFTR in CF lung epithelial cells. We find that the expression of SFPQ is reduced in F508del-CFTR CF epithelial cells compared to WT-CFTR control cells. Interestingly, the overexpression of SFPQ in CF cells increases the expression as well as rescues the function of F508del-CFTR. Further, comprehensive transcriptome analyses indicate that SFPQ plays a key role in activating the mutant F508del-CFTR by modulating several cellular signaling pathways. This is the first report on the role of SFPQ in the regulation of expression and function of F508del-CFTR in CF lung disease. Our findings provide new insights into SFPQ-mediated molecular mechanisms and point to possible novel epigenetic therapeutic targets for CF and related pulmonary diseases.
引用
收藏
相关论文
共 50 条
  • [11] Calcium homeostasis is abnormal in cystic fibrosis airway epithelial cells but is normalized after rescue of F508del-CFTR
    Antigny, Fabrice
    Norez, Caroline
    Becq, Frederic
    Vandebrouck, Clarisse
    [J]. CELL CALCIUM, 2008, 43 (02) : 175 - 183
  • [12] Palmitate accumulation within phospatidylcholine of cystic fibrosis human bronchial epithelial cells: impacts on ER stress and F508del-CFTR trafficking correction
    Payet, L. A.
    Kadri, L.
    Berjeaud, J. M.
    Norez, C.
    Mirval, S.
    Becq, F.
    Vandebrouck, C.
    Ferreira, T.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2014, 28 : 74 - 74
  • [13] RETROSPECTIVE ANALYSIS OF PHYSIOLOGICAL RESPONSE PATTERNS TO TEZACAFTOR/IVACAFTOR IN PATIENTS WITH CYSTIC FIBROSIS HOMOZYGOUS FOR F508DEL-CFTR OR HETEROZYGOUS FOR F508DEL-CFTR AND A RESIDUAL FUNCTION MUTATION
    Ingenito, E.
    Nair, N.
    Yi, B.
    Lekstrom-Himes, J.
    Elborn, J.
    Rowe, S. M.
    [J]. PEDIATRIC PULMONOLOGY, 2018, 53 : 198 - 198
  • [14] RETROSPECTIVE ANALYSIS OF PHYSIOLOGICAL RESPONSE PATTERNS TO TEZACAFTOR/IVACAFTOR IN PATIENTS WITH CYSTIC FIBROSIS HOMOZYGOUS FOR F508DEL-CFTR OR HETEROZYGOUS FOR F508DEL-CFTR AND A RESIDUAL FUNCTION MUTATION
    Ingenito, E.
    Nair, N.
    Yi, B.
    Lekstrom-Himes, J.
    Elborn, J. S.
    Rowe, S. M.
    [J]. THORAX, 2018, 73 : A42 - A43
  • [15] Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR
    Donaldson, Scott H.
    Pilewski, Joseph M.
    Griese, Matthias
    Cooke, Jon
    Viswanathan, Lakshmi
    Tullis, Elizabeth
    Davies, Jane C.
    Lekstrom-Himes, Julie A.
    Wang, Linda T.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197 (02) : 214 - 224
  • [16] Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR
    Rowe, Steven M.
    McColley, Susanna A.
    Rietschel, Ernst
    Li, Xiaolei
    Bell, Scott C.
    Konstan, Michael W.
    Marigowda, Gautham
    Waltz, David
    Boyle, Michael P.
    [J]. ANNALS OF THE AMERICAN THORACIC SOCIETY, 2017, 14 (02) : 213 - 219
  • [17] Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis
    Zhi-wei Cai
    Jia Liu
    Hong-yu Li
    David N Sheppard
    [J]. Acta Pharmacologica Sinica, 2011, 32 : 693 - 701
  • [18] Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
    Flume, Patrick A.
    Liou, Theodore G.
    Borowitz, Drucy S.
    Li, Haihong
    Yen, Karl
    Ordonez, Claudia L.
    Geller, David E.
    [J]. CHEST, 2012, 142 (03) : 718 - 724
  • [19] Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis
    Cai, Zhi-wei
    Liu, Jia
    Li, Hong-yu
    Sheppard, David N.
    [J]. ACTA PHARMACOLOGICA SINICA, 2011, 32 (06) : 693 - 701
  • [20] Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia
    Sondo, Elvira
    Falchi, Federico
    Caci, Emanuela
    Ferrera, Loretta
    Giacomini, Elisa
    Pesce, Emanuela
    Tomati, Valeria
    Bertozzi, Sine Mandrup
    Goldoni, Luca
    Armirotti, Andrea
    Ravazzolo, Roberto
    Cavalli, Andrea
    Pedemonte, Nicoletta
    [J]. CELL CHEMICAL BIOLOGY, 2018, 25 (07): : 891 - +